Frontiers in Oncology (Mar 2023)
Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
- Yurong Peng,
- Zhuo Li,
- Yucheng Fu,
- Yue Pan,
- Yue Zeng,
- Junqi Liu,
- Chaoyue Xiao,
- Yingzhe Zhang,
- Yahui Su,
- Guoqing Li,
- Fang Wu
Affiliations
- Yurong Peng
- Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Zhuo Li
- The Ophthalmologic Center of the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Yucheng Fu
- Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Yue Pan
- Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Yue Zeng
- Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Junqi Liu
- Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Chaoyue Xiao
- Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Yingzhe Zhang
- Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Yahui Su
- XiangYa School of Public Health, Central South University, Changsha, Hunan, China
- Guoqing Li
- XiangYa School of Public Health, Central South University, Changsha, Hunan, China
- Fang Wu
- Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- DOI
- https://doi.org/10.3389/fonc.2023.1163376
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords
- perioperative period perioperative immunotherapy
- neoadjuvant therapies
- immunotherapy
- neoadjuvant immune monotherapy
- adjuvant therapy
- biomarkers
